Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 4/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20989310 | 0.86 | L3MBTL1 (0.50) | SMN1; SMN2L3MBTL1MAPTGAAFKBP1A | |
| SCHEMBL28619936 | 0.85 | SMN1; SMN2 (0.67) | SMN1; SMN2L3MBTL1MAPTLMNAGAA | |
| SCHEMBL24423986 | 0.80 | SMN1; SMN2 (0.53) | SMN1; SMN2MAPTTP53LMNAGAA | |
| SCHEMBL29532645 | 0.79 | SMN1; SMN2 (0.56) | SMN1; SMN2L3MBTL1MAPTFKBP1AMEN1 | |
| SCHEMBL29585773 | 0.75 | HPGD (0.56) | SMN1; SMN2GAAPOLBRECQL | |
| SCHEMBL20989104 | 0.74 | MEN1 (0.53) | SMN1; SMN2L3MBTL1MAPTTP53LMNA | |
| SCHEMBL29532316 | 0.73 | SMN1; SMN2 (0.62) | SMN1; SMN2L3MBTL1MAPTGAAPOLB | |
| SCHEMBL16000506 | 0.73 | MEN1 (0.64) | SMN1; SMN2L3MBTL1MAPTTP53LMNA | |
| SCHEMBL13149405 | 0.72 | MAPT (0.80) | SMN1; SMN2MAPTLMNAMEN1KMT2A | |
| SCHEMBL20989077 | 0.71 | MEN1 (0.58) | SMN1; SMN2L3MBTL1MAPTTP53LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190134056-A1 | K-RAS MUTATIONS AND ANTAGONISTS | THE TRUSTEES OF THE STEVENS INSTITUTE OF TECHNOLOG (US) | 2019-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190134056-A1 | K-RAS MUTATIONS AND ANTAGONISTS | KRAS, NRAS, HRAS | SMN1; SMN2 4615/4885L3MBTL1 1155/4885MAPT 4750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.